💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
HealthCare Global Enterprises Limited is an India-based cancer care provider. The Company offers cancer care, fertility treatment, advanced screening and diagnostic services, and tertiary care. It operates a cancer care network in India in terms of the total number of private…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak, slow-growing business, fairly priced — but flagged on governance.
Healthcare Global Enterprises is scored on the general / industrial framework. It keeps a thin 0.9% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 15.24× reported profit. Free cash flow is worth about 1.9% of its market value.
Over the last 3 years revenue compounded at 15%/yr and profit at 9%/yr. Book value itself has compounded 18%/yr — the hallmark of a genuine compounder. Return on equity is a weak 2.9%. In the latest quarter profit grew 307% versus the prior quarter.
At 168× earnings, the stock sits at the 52nd percentile of its own 3-year range — the middle of where it has historically traded. Today's price already implies ~53%/yr earnings growth sustained for a decade — a demanding bar. The forensic screen raises a red flag: 119% of pre-tax profit is other income, not operations.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 411.4 | — | — |
| P/B | 6.65 | 1.76 | worse |
| EV/EBITDA | 22.06 | 31.87 | better |
| ROE | 2.9 | 10.5 | worse |
| ROCE | 7.81 | — | — |
| ROA | 0.89 | — | — |
| Quick Ratio | 1.06 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 15% CAGR over 3 years — steady double-digit compounder.
Profit is on a 2-year growth streak. Revenue is outpacing profit (15% vs 9%) — costs are rising faster than the top line. The latest year saw a -53% swing — check if it's a one-off or structural.
Operating margin has compressed from 3% to 1% — costs or competition are eating into profitability.
ROE at 2% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. Profit grew faster than EPS (9% vs -23%) — share dilution is eroding per-share value. -23% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 15.2× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 6% sequentially — momentum is building.
1 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 307% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3y median.
Promoter holding at 64.2% — majority control intact. MF holding up 3.7pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.